Navigation Links
Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
Date:7/1/2008

A Complimentary Continuing Education Newsletter Series for Healthcare

Professionals

VOORHEES, N.J., July 1 /PRNewswire/ -- Clostridium difficile infection (CDI) is a serious condition that causes disease with a wide spectrum of severity, ranging from mild diarrhea to pseudomembranous colitis and death. Recurrent CDI can occur in up to 20% of patients who develop an initial case of CDI.(1) These patients are at increased risk of additional recurrences, as well as more complicated disease, including toxic megacolon, colon perforation, and systemic inflammatory response syndrome with organ failure leading to colectomy or death.

To address the need for education on recurrent CDI, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a 3-part series of complimentary educational newsletters targeted to primary care physicians. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease is the first newsletter of this series.

The Expert Faculty for this continuing education activity include Ciaran P. Kelly, MD, Associate Professor of Medicine at Harvard Medical School, Director of Gastroenterology Fellowship Training at Beth Israel Deaconess Medical Center, and Chief of Hermann L. Blumgart Internal Medicine, and Vivian G. Loo, MD, MSc, FRCPC, Chief of the Department of Microbiology at McGill University Health Centre.

Healthcare professionals can receive this self-study activity by downloading or ordering online at http://www.rmei.com/CDInewsletters.

Healthcare professionals who treat patients with CDI should take advantage of this opportunity to learn about the management of patients with recurrent CDI.

This continuing education opportunity is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine and is supported by an educational grant from ViroPharma Incorporated.

Robert Michael Educational Institute LLC is a full-service medical education company dedicated to providing comprehensive medical education to healthcare providers, patients, and caregivers. Our mission is to design programs that improve diagnosis and treatment through a variety of educational programming such as national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit http://www.RMEI.com.

(1) McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43-50.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
3. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
4. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
5. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
6. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
7. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
8. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
9. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
10. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
11. APIC Launches Targeting Zero Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016   Mallinckrodt Pharmaceuticals ... pharmaceutical company, today announced that it received a perfect ... Index (CEI), a national benchmarking survey and report on ... and transgender (LGBT) workplace equality, administered by the Human ... 517 major U.S. businesses which also earned top marks ...
(Date:12/5/2016)... 5, 2016  Cornerstone Pharmaceuticals, Inc., a privately ... from two Phase I trials evaluating its lead ... annual meeting of the American Society of Hematology ... . The two datasets show encouraging efficacy and ... (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, ...
(Date:12/5/2016)... BOULDER, Colo. , Nov. 29, 2016 ... webinar hosted by Accera, Inc. at 11 ... 9th Annual International Conference on Clinical Trials for Alzheimer,s ... role of metabolism in Alzheimer,s disease and therapeutic targets ... patients. "Following the recent failure of another ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 2016 , ... CarriersEdge, providers of online safety and compliance training tools for ... Offered in three modules, the courses can be used as an extension to an ... how to stay healthy on the road. , “CarriersEdge is now offering a way ...
(Date:12/6/2016)... ... 06, 2016 , ... Of the variety of ingredients in the food supply, ... contrary to common beliefs that hot dogs include “everything but the oink,” today’s wieners ... Ingredients combined with meat and poultry in a hot dog recipe can add flavor, ...
(Date:12/6/2016)... ... December 06, 2016 , ... The NALA, a boutique marketing agency, is ... Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families ... To assist TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... Autism Center with an Award of Distinction, recognizing the organization as a top ... that excel in the areas of clinical quality, staff satisfaction and qualifications, and ...
(Date:12/6/2016)... Yorba Linda, Ca (PRWEB) , ... December 06, ... ... one of the fastest growing fields in research and development, largely due to ... investigated, including human mesenchymal stem cells (hMSCs) and human induced pluripotent stem cells ...
Breaking Medicine News(10 mins):